BI 3006337

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyNon-alcoholic Fatty Liver DiseaseObesity

Phase 1

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

CompletedNCT05076422

Boehringer IngelheimHealthy

Start: 2021-10-18End: 2023-03-03Updated: 2026-01-08

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

CompletedNCT05970640

Boehringer IngelheimNon-alcoholic Fatty Liver Disease, Obesity

Start: 2023-08-14End: 2024-11-07Updated: 2025-12-05

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

CompletedNCT06310005

Boehringer IngelheimHealthy

Start: 2024-04-19End: 2024-10-31Updated: 2025-12-22